The opening of the 21st century has been heralded as a turning point in biomedical research. The completesequence and a dense map of the human genome, coupled with advanced genomics technologies holds thepromise of dramatically accelerating the understanding of human disease, which in turn is expected toaccelerate the pace of discovery of new therapeutics. Similarly, recent advances in synthetic organicchemistry have the potential to greatly improve chemical screening and compound optimization.In principle, these technical and conceptual advances have the potential to transform drug discovery. Inpractice, however, they have not yet done so. While emerging genomic and chemical technologies areavailable in isolation, they have not been creatively integrated into the drug discovery process. A key reasonhas been the lack of a concerted, interdisciplinary effort to merge the disciplines of genetics and chemistryinto a new conceptual framework.We propose here an ambitious plan to create a new approach to drug discovery involving four components. Component A (U54 Leadership) which includes the IRC Steering Committee. Component B (Discovery Pipeline). This component aims to develop a drug discovery pipeline based on the paradigm of phenotypic screening. This includes developing i) systematic high-throughput screening of phenotypic assays for cellular states based on gene-expression and imaging; ii) expanded libraries of DOS compounds to facilitate high-throughput screening, target identification and medicinal chemistry optimization; and iii)genomics-based approaches to predictive toxicology. Component C (Target ID).This component aims to develop systematic approaches to identifying the protein target of a small molecule based on i) techniques for affinity capture and proteomic analysis; ii) novel approaches using RNA inhibition (RNAi); and iii) novel computational approaches to recognize distinctive cellular signatures. Component D (Driving Medical Projects). To drive its development and test its utility, the new paradigm must be applied to specific biomedical problems. This component will undertake six demonstration projects.
| Chou, Danny Hung-Chieh; Vetere, Amedeo; Choudhary, Amit et al. (2015) Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling. J Am Chem Soc 137:7929-34 |
| Dan?ík, Vlado; Carrel, Hyman; Bodycombe, Nicole E et al. (2014) Connecting Small Molecules with Similar Assay Performance Profiles Leads to New Biological Hypotheses. J Biomol Screen 19:771-81 |
| Schenone, Monica; Dan?ík, Vlado; Wagner, Bridget K et al. (2013) Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 9:232-40 |
| Hartwell, Kimberly A; Miller, Peter G; Mukherjee, Siddhartha et al. (2013) Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol 9:840-848 |
| Ong, Shao-En; Li, Xiaoyu; Schenone, Monica et al. (2012) Identifying cellular targets of small-molecule probes and drugs with biochemical enrichment and SILAC. Methods Mol Biol 803:129-40 |
| Bray, Mark-Anthony; Fraser, Adam N; Hasaka, Thomas P et al. (2012) Workflow and metrics for image quality control in large-scale high-content screens. J Biomol Screen 17:266-74 |
| Pandya, Bhaumik A; Dandapani, Sivaraman; Duvall, Jeremy R et al. (2011) Practical asymmetric synthesis of ?-hydroxy ?-amino acids via complimentary aldol reactions. Tetrahedron 67:6131-6137 |
| Comer, Eamon; Liu, Haibo; Joliton, Adrien et al. (2011) Fragment-based domain shuffling approach for the synthesis of pyran-based macrocycles. Proc Natl Acad Sci U S A 108:6751-6 |
| Pan, Jen Q; Lewis, Michael C; Ketterman, Josh K et al. (2011) AKT kinase activity is required for lithium to modulate mood-related behaviors in mice. Neuropsychopharmacology 36:1397-411 |
| Raj, Lakshmi; Ide, Takao; Gurkar, Aditi U et al. (2011) Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475:231-4 |
Showing the most recent 10 out of 18 publications
